Strong Positive Movement for Applied Therapeutics Stock
Recently, Applied Therapeutics, Inc. experienced a remarkable surge in its stock price, alongside an impressive jump in trading volume. During one trading session, the company’s shares rose dramatically, with a significant 31.75 million shares changing hands, tremendously outpacing the average trading volume of 1.26 million shares.
Update on New Drug Application
This spike follows the company’s announcement about the ongoing review of its New Drug Application (NDA) for govorestat, which aims to treat Classic Galactosemia. This is a hereditary metabolic disorder that hampers the body's ability to properly process galactose, a simple sugar found in various foods.
FDA Guidelines and Expectations
In an important development, the company completed a late-cycle review meeting with the FDA. The agency indicated that it wouldn't require an Advisory Committee meeting that was tentatively planned for a future date. Instead, they confirmed that the Priority Review of the NDA would remain on schedule, with further discussions regarding post-marketing requirements anticipated down the line.
Upcoming Action Dates
Moreover, the Prescription Drug User Fee Act (PDUFA) target action date for this review is still set for the end of November. This timeline supports the ongoing momentum towards potentially launching this crucial treatment soon.
Anticipated Launch and Market Potential
Financial analysts, including those from William Blair, predict that Applied Therapeutics may introduce govorestat to the galactosemia market by 2025. The expectations are high, given the considerable unmet medical needs in this area and the lack of approved therapies currently available for patients.
Sales Projections
Analysts estimate that sales for govorestat could surpass $1 billion by 2030, provided the company captures about 70% of the market in the galactosemia sector. This represents an exciting opportunity for investors as the company makes strides with its innovative therapies.
Stock Performance Overview
As of the most recent update, Applied Therapeutics saw substantial gains in its stock price. The shares have increased by 71.40%, reaching $7.97. This positive trend reflects the favorable investor sentiment, driven by the FDA's supportive approach to the company’s new drug application.
Conclusion
The rising interest in Applied Therapeutics and its innovative treatment for Classic Galactosemia marks a significant moment in the biotech landscape. With the FDA review proceeding smoothly and promising market potential ahead, optimism about the company's future appears to be growing.
Frequently Asked Questions
What triggered the increase in Applied Therapeutics stock?
The stock rose sharply after the FDA announced that an Advisory Committee meeting would not be necessary for the review of govorestat, along with a notable surge in trading volume.
What is govorestat developed for?
Govorestat is intended to treat Classic Galactosemia, a genetic metabolic disorder that impedes the body's ability to process galactose effectively.
When is the PDUFA target action date for govorestat?
The target action date set by the Prescription Drug User Fee Act is scheduled for November 28.
What are the market expectations for govorestat?
Analysts forecast that govorestat could achieve sales surpassing $1 billion by 2030, capturing around 70% of the galactosemia market.
What was the recent stock price for APLT?
Recently, APLT stock was noted to be trading at $7.97, reflecting a substantial increase of 71.40%.
